AtCor secures $1.5m cardiovascular trial contract
pharmaceutical company with central blood pressure reading and
clinical trial support services in a deal worth $1.48m (€1.2m).
The multi-centre cardiovascular drug trial will take place over an estimated 30 months in the US.
AtCor Medical is the developer of the SphygmoCor technology, which it says enables, for the first time, non-invasive measurement of central blood pressures and other key heart function parameters.
The technology that powers SphygmoCor is centred on a transfer function - a patented mathematical model of the properties of the brachial artery - that derives the pressure wave at the ascending aorta, providing central data through a recording of the pressure wave at the radial artery.
According to the firm, pharmaceutical and research companies are increasingly turning to SphygmoCor to document the true cardiovascular effects of their compounds.
"Central pressure data is becoming key to determining the true cardiovascular impact of new drugs," said Ross Harricks, CEO AtCor Medical.
"Using SphygmoCor, companies have the potential to gain market advantage by demonstrating the physiological benefits of new and current drugs, and also to make better-informed go/no go decisions earlier in the drug development process."
The firm cited the recent example of the Anglo-Scandinavian Cardiac Outcomes (ASCOT) and Conduit Artery Function Evaluation (CAFE) antihypertensive trials, where central blood pressure measurements were used to explain differences in outcomes between the drug regimens studied.
